VECTIVBIO
VectivBio is a clinical-stage biotechnology company bringing transformational medicines to patients with serious rare diseases. They are committed to pursuing rare diseases with well-defined biology that can be targeted with best-in-disease therapies that have the potential to meaningfully transform and improve the lives of patients and their families, not just provide an incremental improvement or benefit over the standard-of-care. It was founded as a spinout from Therachon, a biotechnology company acquired by Pfizer for its program in achondroplasia. VectivBio was incorporated in 2019 and is based in Basel, Switzerland.
VECTIVBIO
Industry:
Biotechnology Health Care Medical
Founded:
2019-01-01
Address:
Basel, Basel-Stadt, Switzerland
Country:
Switzerland
Website Url:
http://www.vectivbio.com
Total Employee:
51+
Status:
Active
Total Funding:
399 M USD
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta SPF Apple Mobile Web Clips Icon Google Font API Google Tag Manager WordPress Google Analytics Content Delivery Network Amazon
Similar Organizations
Bactobio
Bactobio is a biotechnology company unlocking biodiversity for a greener and safer world.
Dermavant Sciences
Dermavant Sciences is a biotechnology company focused on dermatology.
Eikon Therapeutics
Eikon Therapeutics is a biopharmaceutical company that develops live-cell resolution microscopy and engineering for drug discovery.
Kinarus Therapeutics (SIX:KNRS)
Kinarus is focused on developing novel treatments for patients suffering from serious viral, respiratory, and ophthalmic diseases.
mybacs
mybacs is a Biotechnology company specialized in the human microbiome.
Numab
Numab is a biotechnology company that offers antibody-based therapeutics for the treatment of severe diseases.
Ocean Biomedical
Ocean Biomedical is a biotechnology company that accelerates new discoveries in the world of medicine.
Prolocor
Prolocor is a biotechnology company that develops diagnostic tests for cardiovascular diseases.
Q32 Bio
Q32 Bio is a biotechnology company that develops treatments for patients with severe autoimmune and inflammatory diseases.
Teitur Trophics
Teitur Trophics is a biotech company developing novel treatments for neurodegenerative diseases.
Current Advisors List
Board_member
2019-07-01
Board_member
Board_member
Current Employees Featured
Christian Meyer Chief Development Officer @ VectivBio
Chief Development Officer
2019-01-01
Alain Bernard Chief Technology Officer @ VectivBio
Chief Technology Officer
Graham Morrell Investor Relations @ VectivBio
Investor Relations
2021-01-01
Claudia D’Augusta Chief Financial Officer @ VectivBio
Chief Financial Officer
Mary Weger Interim CHRO @ VectivBio
Interim CHRO
2018-09-01
Diego Ramos Rodriguez Senior Director, Head of Group Accounting & Reporting at VectivBio AG @ VectivBio
Senior Director, Head of Group Accounting & Reporting at VectivBio AG
2022-06-01
Scott Applebaum Chief Legal Officer & Corporate Secretary @ VectivBio
Chief Legal Officer & Corporate Secretary
2021-09-01
Luca Santarelli Founder and Chief Executive Officer @ VectivBio
Founder and Chief Executive Officer
2019-06-01
Kevin Harris Chief Commercial Officer @ VectivBio
Chief Commercial Officer
Mary Carmen Diez Global Medical Affairs @ VectivBio
Global Medical Affairs
2019-01-01
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2021-08-31 | Comet Therapeutics | Comet Therapeutics acquired by VectivBio | N/A |
Investors List
OrbiMed
OrbiMed investment in Post-IPO Equity - VectivBio
Surveyor Capital
Surveyor Capital investment in Post-IPO Equity - VectivBio
Forbion Capital Partners
Forbion Capital Partners investment in Post-IPO Equity - VectivBio
Vivo Capital
Vivo Capital investment in Post-IPO Equity - VectivBio
TCG Crossover
TCG Crossover investment in Post-IPO Equity - VectivBio
Driehaus Capital Management
Driehaus Capital Management investment in Post-IPO Equity - VectivBio
Eventide
Eventide investment in Post-IPO Equity - VectivBio
Frazier Life Sciences
Frazier Life Sciences investment in Post-IPO Equity - VectivBio
Venrock Healthcare Capital Partners
Venrock Healthcare Capital Partners investment in Post-IPO Equity - VectivBio
Marshall Wace
Marshall Wace investment in Post-IPO Equity - VectivBio
Key Employee Changes
Official Site Inspections
http://www.vectivbio.com
- Host name: 172.67.74.109
- IP address: 172.67.74.109
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "VectivBio"
VectivBio - Crunchbase Company Profile & Funding
VectivBio is a clinical-stage biotechnology company bringing transformational medicines to patients with serious rare diseases. They are committed to …See details»
VectivBio AG - Company Profile & Staff Directory - ContactOut
VectivBio AG is a clinical-stage biotechnology company focused on rare diseases with a well-defined biology that can be targeted with transformational therapeutics. VectivBio was formed …See details»
VectivBio Company Profile | Management and Employees List
VectivBio Profile and History. VectivBio (Nasdaq: VECT) is a global, clinical-stage biotechnology company focused on the discovery, development and commercialization of innovative …See details»
VectivBio AG: Contact Details and Business Profile
VectivBio AG is a clinical-stage biotechnology company focused on rare diseases with a well-defined biology that can be targeted with transformational therapeutics. VectivBio was formed …See details»
VectivBio Company Profile - Office Locations, Competitors ... - Craft
Jul 17, 2023 VectivBio a biotechnology company focused on the discovery, development, and commercialization of treatments for severe rare conditions. It develops transformational …See details»
VectivBio Company Profile 2024: Valuation, Investors ... - PitchBook
VectivBio Holding AG is a clinical stage biopharmaceutical company. It is focused on the discovery, development and commercialization of innovative treatments for severe rare …See details»
VectivBio - Overview, News & Similar companies | ZoomInfo.com
VectivBio's product candidate, apraglutide, is a next-generation GLP-2 analog being developed as a differentiated therapeutic for a range of rare gastrointestinal diseases. ... Business …See details»
VectivBio - Products, Competitors, Financials, Employees, …
About VectivBio. VectivBio is a clinical-stage biotechnology company focused on developing treatments for severe rare diseases. The company's main offerings include the discovery, …See details»
VectivBio AG Company Profile | Basel, BASEL-STADT, Switzerland ...
Find company research, competitor information, contact details & financial data for VectivBio AG of Basel, BASEL-STADT. Get the latest business insights from Dun & Bradstreet.See details»
VectivBio - Company Profile - Tracxn
Dec 9, 2024 VectivBio. has raised a total funding of $145M over 3 rounds. Its first funding round was on Jan 07, 2020. What are the most recent funding rounds of VectivBio? Its latest funding …See details»
VectivBio Headquarters and Office Locations - Craft.co
VectivBio. Overview; Locations; Financials; Operating Metrics; Human Capital; Key People; Competitors; Supplier Risk; VectivBio Headquarters and Office Locations. Header placeholder …See details»
VectivBio - Funding, Financials, Valuation & Investors - Crunchbase
VectivBio is registered under the ticker NASDAQ:VECT . Their stock opened with $17.00 in its Apr 8, 2021 IPO. VectivBio is funded by 18 investors. OrbiMed and Surveyor Capital are the most …See details»
VectivBio — CTI Life Sciences
VectivBio AG is a late clinical-stage biotechnology company focused on rare conditions with well-defined biology that can be targeted with transformational therapeutics. VectivBio was formed …See details»
VectivBio - Org Chart, Teams, Culture & Jobs - The Org
View VectivBio's up-to-date org chart, open roles, and culture details. Find executives, board members, teams, related companies, and more.See details»
VectivBio Holding AG - Drug pipelines, Patents, Clinical trials
The remaining outstanding VectivBio Shares are expected to be settled by Ironwood in cash. Workforce Reductions and Restructuring In April 2023, Ironwood reduced its workforce by …See details»
VectivBio - Updates, News, Events, Signals & Triggers - Crunchbase
VectivBio is focused on developing innovative treatments for rare diseases, as evidenced by their research into GLP-2 analog peptides and macrocyclic pantetheine derivatives. Their work …See details»
VectivBio CEO and Key Executive Team | Craft.co
VectivBio's Founder and Chief Executive Officer and Board Member is Luca Santarelli. Other executives include Claudia D'Augusta, Chief Financial Officer; Alain Bernard, Chief …See details»
VectivBio - Contacts, Employees, Board Members, Advisors & Alumni
Organization. VectivBio . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. Highlights. Employee Profiles 10. ... VectivBio has 3 …See details»
VectivBio - Forbion
VectivBio AG is a global, clinical-stage biotechnology company developing innovative treatments for severe rare conditions with significant unmet medical need. The company is committed to …See details»
VectivBio AG - startup.ch
VectivBio AG: We have a world-class team with deep expertise in rare diseases and a track record of success in Research & Development commercialization and business development …See details»